Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens (Q34265381)

1 August 2017

1 reference

title

Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens (English)

1 reference

1 August 2017

1 reference

1 reference

1 August 2017

Maecker B

1 reference

1 August 2017

von Bergwelt-Baildon MS

series ordinal

1 reference

1 August 2017

Anderson KS

series ordinal

1 reference

1 August 2017

Vonderheide RH

series ordinal

1 reference

1 August 2017

publication date

1 February 2001

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

81-89

1 reference

A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Tumor immunology: the first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Tumor antigens recognized by T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

The makings of a tumor rejection antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

A new era for cancer immunotherapy based on the genes that encode cancer antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Phenotypic analysis of antigen-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

T cell defined tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Serological identification of human tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillanc

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Evolution of a complex T cell receptor repertoire during primary and recall bacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Specific Association of Human Telomerase Activity with Immortal Cells and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Cytotoxic T cell immunity against telomerase reverse transcriptase in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Expression of TERT in early premalignant lesions and a subset of cells in normal tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Creation of human tumour cells with defined genetic elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Inhibition of telomerase limits the growth of human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Mutated Ras peptides as vaccines in immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Self-tolerance and the composition of T cell repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

DNA immunization induces protective immunity against B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Prospects for adoptive T cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Immune surveillance against a solid tumor fails because of immunological ignorance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Reverse ELISPOT assay for clonal analysis of cytokine production I. Enumeration of gamma-interferon-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

21 January 2018

A new look for the 1990s

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2001.00014.X

10.1046/J.1423-0410.2001.00014.X

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference